Study of hepatotoxicity of naltrexone in the treatment of alcoholism

Alcohol

Volumn 38, Issue 2, 2006, Pages 117-120

  Yen, Mao Hsiung ^a   Ko, Huei Chen ^b   Tang, Fu In ^c   Lu, Ru Band ^b,d   Hong, Jau Shyong ^e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Alcohol dependence; Hepatotoxic; Liver enzymes: ALT and AST; Naltrexone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; NALTREXONE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ALCOHOLISM; ASPARTATE AMINOTRANSFERASES; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; TIME FACTORS;

EID: 33745726938     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2006.05.003     Document Type: Article

References (13)

1. Atkinson R.L., Berke L.K., Drake C.R., Bibbs M.L., Williams F.L., and Kaiser D.L. Effects of long term therapy with naltrexone on body weight in obesity. Clin Pharm Ther 384 (1985) 19-22
2. Brahen L.S., Capone T.J., and Capone D.M. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol 2 (1988) 64-70
3. Brewer C., and Wong V.S. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol 9 (2004) 81-87 and references therein
4. Croop R.S., Faulkner E.B., and Labriola D.F. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 54 (1997) 1130-1135
5. Endicott J., and Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35 7 (1978) 837-844
6. Grant J.E. Outcome study of kleptomania patients treated with naltrexone: a chart review. Clin Neuropharmacol 28 1 (2005) 11-14
7. Knopman D.S., and Hartman M. Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease. J Neurol Neurosurg Psychiatry 49 (1986) 1321-1322
8. Malcolm R., O'Neil P.M., Sexauer J.D., Riddle F.E., Currey H.S., and Counts C. A controlled trial of naltrexone in obese humans. Int J Obes 9 5 (1985) 347-353
9. Mitchell J.E., Morley J.E., Levine A.S., Hatsukami D., Gannon M., and Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22 1 (1987) 35-42
10. Mosby's Drug Consult. Naltrexone Hydrochloride (001857). Copyright © (2005), Mosby, Inc. MDconsult. http://home.mdconsult.com
11. Pfohl D.N., Allen J.I., Atkinson R.L., Knopman D.S., Malcolm R.J., Mitchell J.E., and Morley J.E. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67 (1986) 66-72
12. Sax D.S., Kornetsky C., and Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 34 (1994) 898-901
13. Swendsen J.D., Merikangas K.R., Canino G.J., Kessler R.C., Rubio-Stipec M., and Angst J. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry 39 4 (1998) 176-184